Adicet Bio: Building the Next Generation of Cellular Therapies

BY kyrstin
May 2, 2019

Adicet Bio is harnessing the innate allogeneic potential of gamma delta (γδ) T cells to treat solid and liquid tumors. Jeanette Grant, Associate Director of Project Management, discussed the unique challenges in developing these cutting-edge therapeutics, and how Benchling is changing the way Adicet organizes and carries out R&D. Adicet is using Benchling across research teams to power data management and collaboration.

Visit our customer stories page to lean how more companies are powering their life science R&D with Benchling.

You can find information on upcoming Benchling events here, or check out the following posts for more articles and videos of Benchtalk West.


Published by kyrstin
VIEW ALL POSTS BY kyrstin

Leave a Reply

%d bloggers like this: